Pharmaceutical Technology Editors

Lilly Diabetes supports the American Diabetes Association for the seventh year in a row.

MedImmune and AstraZeneca enter a three-year collaboration with the Clinical and Translational Science Institute at the UC San Francisco.

Discovery of split and broken tablets led to drug recalls.

Experts note hepatitis C screening is important for getting care early.

Moody's Investor Service reports AbbVie, Amgen, and Roche are the most exposed to biosimilar competition.

Almac has added new blistering technology at their US packaging facility in Audubon, PA, as a solution to ease the transition between clinical and commercial launch of blister products.

FDA revises interpretation of the five-year NCE exclusivity provisions for certain fixed-combination drug products.

Daiichi Sankyo announced suspension of API shipments from Ranbaxy's Toansa and Dewas plants; issues apology to stakeholders.

FDA and EMA set up regular meetings to harmonize drug safety actions.

The combined company will create blockbuster product franchises in the central nervous system, gastroenterology, women's health, urology, and cardiovascular therapeutic categories.

FDA provides recommendations for submitting analytical procedures and methods validation data.

Thirteen companies are accepted for participation in the supply chain program.

Tandem Diabetes Care expands its voluntary recall of select lots of insulin cartridges used with t:slim insulin pump.

Cobra Biologics' GMP Compliance Certification has been extended to include QC testing.

NSF-IPEA now can provide excipient auditing and certification.

EMA releases an update on its flu vaccine guidance.

EMA and the European Commission revise Q&A document on implementation of marketing authorization guidelines.

The companies will pre-promote their auto-injection syringe inspection platform at ATX West.

Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.

Mylan Pharmaceuticals launches Hertraz, the world's first trastuzumab biosimilar in India.

Sartorius appoints Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division.

Shimadzu's new Solution Center features additional research space.

In first official visit to India, FDA commissioner to discuss ongoing collaboration on drug programs.

BioOutsource will open a new Biosimilar Center of Excellence in Scotland.

Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.

Edison and DSP partner to develop drugs targeting cellular energy metabolism.

BASF receives EXCiPACT Certification for the group of polyvinylpyrrolidone polymers, produced in Germany.

I Holland announces service that predicts solutions for tablet sticking problems.

Regis Technologies passes a recent FDA audit with no Form 483 observations.

Avantor Performance Materials adds VWR International locations to its certified excipient distributor program.